Cardiol Therapeutics Inc. (NASDAQ: CRDL) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT CARDIOL THERAPEUTICS INC.

Cardiol Therapeutics Inc. (NASDAQ: CRDL)
Listen to this Section


$1.13
-0.0250 ( -2.17% ) 283.2K

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Clinical Trial Pipeline Stages


Drug Name Stage
CardiolRx™DetailsCOVID-19 Failed
CardiolRx™DetailsAcute Myocarditis Phase 2
CardiolRx™DetailsRecurrent pericarditis Phase 2/3

Market Data


Open $1.13
Previous Close $1.15
Volume 283.2K
Market Cap $129.11M
Day Range $1.12 - $1.16
52 Week Range $0.88 - $1.71
Shares Outstanding 115.27M
Change % -2.17%
Net Change ▼ -0.0250
Insider Ownership N/A
Exchange NASDAQ
SectorHealthcare
IndustryPharmaceuticals and Biotechnology
IPO Year2019
CountryCanada

Insider Ownership Transactions

Total Amount Purchased: 0.00

Date Type Amount Purchased Purchaser
No records found.

SEC Filings


Form Type Description Pages Date
6-k Form 6-K 3 Jul 22, 2025

Latest News


× Before browsing our site, please accept our cookies policy